China’s genomics powerhouse BGI resumed Tuesday its application for a listing on the Growth Enterprises Market (GEM) board on the Shenzhen Stock Exchange, after being stuck in the country’s clogged pipeline for one year, local media is reporting. Earlier the genomics giant’s IPO review was suspended due to incomplete documents.

If successful, the listing may make the company’s market cap top RMB 100 billion, according to an earlier report (in Chinese).

Dubbed the “Tencent of China’s biology sector”, BGI is one of the leading genome sequencing centers in the world.  Its five largest customers include China National Tobacco Corporation and the University of Oxford.

Start your free trial now.

Get instant access to all our premium content, archives, newsletters, and online community.

Monthly Membership

Yearly Membership

What you get

Full access to all premium content and our full archives

Members'-only newsletters

Preferential access and discounts to all TechNode events

Direct access to the TechNode newsroom

Start your free trial now.

Get instant access to all our premium content, archives, newsletters, and online community.

Monthly Membership

Yearly Membership

Sheila Yu

Sheila Yu is a Shanghai-based technology writer. She brings readers the biggest news from Chinese language tech media. Reach her at sheila@technode.com.